Download the White Paper:

A Risk-Based Approach to 21 CFR Part 11

The Food and Drug Administration has withdrawn some of its guidance for field staff that monitor pharmaceutical companies’ compliance with 21 CFR Part 11. In this white paper, Tompkins runs down what has changed and suggests how companies should respond to the situation.

Register below to download the complete report.